高新区博安生物创新药全产业链项目：打破多项技术壁垒

　　Boan Biotech Innovative Drug Industry Chain Project of Gaoxin (High-tech) District :

　　Break a Number of Technical Barriers

　　博安生物是绿叶集团旗下第二家上市公司，聚焦肿瘤、免疫等疾病，进行生物药的开发、生产和商业化。项目总投资30亿元，占地85亩，一期2021年4月投产，二期2024年竣工达产，预计今年产值超过十亿，5年产值将突破百亿。作为高新区本土孵化培育的2022年香港主板上市企业，“蝶变”之路，展现了高新区生物医药产业“研发-中试-产业化”的全链条成长规律。

　　Boan Biotech is the second listed company under Luye Pharma, which focuses on the development, production and commercialization of biological drugs for cancer, immunity and other related diseases. The total investment of the project is 3 billion yuan, covering an area of 85 acres. The first phase has been put into operation since April 2021, while the second phase will be completed in 2024, and the output value is expected to exceed 1 billion this year and will exceed 10 billion in 5 years. As a company listed on the main board of Hong Kong in 2022, its journey towards a metamorphosis shows a whole-chain growth of Gaoxin (high-tech) Distric, which follows the path of R&D, pilot test, industrialization.

　　深耕研发，培根筑基。累计研发投入超过20亿，带动企业井喷式发展，目前开发12款生物药，2款已在国内上市、4款正在进行上市冲刺、6款进入临床，研发速度全国第一。其中，博优倍为全球首个获批上市的地舒单抗生物类似药，被评为“2022年中国医药生物技术十大进展”。

　　With deep research and development, solid roots and foundation, the project has an accumulative investment of more than 2 billion, which drives its soaring development. Currently, it has developed 12 biological drugs with 2 have come into domestic market and 4 getting prepared. Another 6 already go into clinic trial, the research and development speed ranks top across the country. Among them, Boyoubi is the world's first disuzumab biosimilar drug that is approved to go into the market and was rated as one of the Top 10 Pharmaceutical Biotechnology Progress of China in 2022.

　　强建平台，赋能加速。搭建三大自主创新技术平台，其中，全人抗体转基因小鼠技术平台是国内首创、业内最好的小鼠平台，通过将人的抗体基因片段植入小鼠体内，使小鼠直接产生人类抗体，药品研发成功率提升3倍，研发周期缩短1/2。

　　A strong platform shall enable the acceleration of development. It has three independent-built innovation technology platforms , among which, the whole-human antibody transgenic mouse technology platform is the first mouse platform in China and the best within the industry. By implanting human antibody gene fragments into mice, mice can directly produce human antibodies, increasing the success rate of drug research and development by 3 times and shortening the research and development cycle by 1/2.

　　布局全球，引才聚智。在美国、日本、德国、新加坡等世界医药领先地区布局研发机构，建立了与全球先进技术接轨的国际化专业团队，拥有国际高层次人才领衔的研发人员285人，硕博占比85%以上，强大的人才团队打破多项技术壁垒，获得国内外发明专利31项、待批专利45项，在细胞株培养方面攻克了国外“卡脖子”技术，实现国产替代；在实体瘤抗体技术方面位居全球第二、中国第一，实现从追赶者到领跑者的跨越。

　　Laying out globally shall gather talents and wisdom. By establishing R&D institutions in United States, Japan, Germany, Singapore and other pharmaceutically leading areas of the world, Boan Biotech has set up professional teams in line with world's advanced technology. With 285 high-level international R&D personnel, 85% of whom own master or doctoral degrees, this strong talent team has broken a number of technical barriers, obtained 31 domestic and foreign invention patents and another 45 pending for approval. In terms of cell strain culture, they overcome choke-point technology and replaced foreign solution with domestic substitution. In terms of solid tumor antibody technology, it ranks second in the world and first in China, achieving a leap from a pursuer to a leader.

　　博安生物已进入高速成长期，市区两级将继续在孵化场地、研发投入、人才奖励、资本加持等方面全力赋能，加快推动博洛佳、度拉糖肽等10款创新药，60余款2类及以上医疗器械获批上市，为“创新好药烟台制造”金字招牌贡献“高新”力量。

　　Boan Biotech has entered a high-speed growth period, both city and district administrations will continue to fully support the project in terms of offering incubation sites, research and development investment, talent rewards, financial aids and so on, to accelerate the promotion of 10 innovative drugs and help with more than 60 type-2 and above medical devices get approved for the market, contributing its own forces for made-in-Yantai innovative good drug.